Technological projects portfolio


Vaccine adjuvant

Investment: €734k

Scope: Healthcare

Scientific field(s): Biology and medicinal chemistry

Institution(s): Université de Versailles Saint-Quentin-en-Yvelines - CNRS - BEBSM

Development: Technology to be marketed

#Vaccines #AluminumAdjuvants #MOF


Aluminum salts are the adjuvants of reference for toxoid vaccines. They are necessary to trigger strong, long-lasting immunization. However, these adjuvants are not broken down in the human body and leave permanent deposits: internal tattoos.

The fear is that these deposits could be associated with undesirable side effects, which has led to significant mistrust of vaccines and the risk of a regression in vaccination coverage.

Despite intensive research, the alternatives that have been developed still do not present a risk-benefit ratio as advantageous as that of the aluminum adjuvants.


The EVAC project aims to develop absorbable adjuvants. They are progressively broken down in the body, which makes it possible to initiate an immune response before the adjuvant has dissolved, and therefore prevent the formation of deposits by accumulation.


The EVAC technology is intended for the inactivated and toxoid vaccine markets, where adjuvants are required.

These vaccines represent ¾ of all pediatric vaccines: a decrease in potential side effects and improved trust in these vaccines is crucial to ensure maximum vaccination coverage for most childhood diseases.